What is the primary reason for the changes in director compensation?

The primary reason for the changes is to ensure that CME Group's director compensation is competitive and aligns with market standards, specifically targeting the 50th percentile. This is intended to help attract and retain highly qualified individuals for the Board of Directors, acknowledging the significant time commitment involved in their roles.

How has the equity compensation for directors changed?

The annual equity compensation for non-executive directors has shifted from a fixed grant of 100 shares to an award of Class A shares valued at $75,000. A key new requirement is that directors must maintain at least half of each annual equity stipend until they cease to serve on the Board, promoting a longer-term alignment with shareholder interests.

Were all directors' compensation affected by these changes?

No, these changes specifically apply to the compensation of non-executive directors. The compensation for the Chairman, Mr. Duffy, remained unchanged. He continues to receive an annual cash stipend and an annual grant of 100 shares of stock, without additional compensation for meeting attendance.

What is the significance of the new equity retention requirement for directors?

The requirement for directors to hold at least half of their annual equity stipend until the end of their service is significant because it directly aligns their financial interests with the long-term performance and value of CME Group's stock. This can be viewed as a measure to encourage sustained commitment and focus on shareholder value creation.

CME 8-K: Material Agreements

Summary

CME Group Inc. (CME) filed an 8-K report on August 7, 2006, disclosing material changes to its non-executive director compensation program, effective August 2, 2006. The primary objective of these adjustments is to align director compensation with market standards, specifically targeting the 50th percentile, to attract and retain highly qualified individuals given the substantial time commitment required. These changes reflect the Board's recognition of the critical role directors play in strategic guidance and oversight. The report details specific increases in annual cash stipends, equity grants, and committee meeting fees. Notably, directors are now required to retain a significant portion of their equity awards, indicating a focus on aligning director interests with long-term shareholder value. Compensation for committee chairs and specific roles like the Chairman of the Board Nominating Committee and the Competitive Marketing Advisory Council were also revised upwards. In contrast, the compensation for the Chairman, Mr. Duffy, remained unchanged.

Key Highlights

1Non-executive director compensation significantly increased, including cash stipends and equity awards.
2Annual cash stipend for non-executive directors rose from $17,500 to $25,000.
3Annual equity stipend for non-executive directors changed to a value of $75,000 in Class A shares, replacing a fixed 100-share grant.
4Directors are now required to hold at least half of their annual equity stipend until the end of their service.
5Committee meeting fees increased to $1,500 per meeting for Audit, Compensation, Governance, Board Nominating, and Market Regulation Oversight Committees.
6Compensation for Committee Chairs and specific roles like the Chairman of the Board Nominating Committee and Competitive Marketing Advisory Council were adjusted upwards.
7Compensation for the Chairman, Mr. Duffy, remained unchanged.

CME GROUP INC. 8-K Report, Material Agreement (Aug 7, 2006)

Summary

Key Highlights

Frequently Asked Questions